key: cord-0878449-ai62bjvl authors: Zhang, Hang; Deng, Shasha; Ren, Liting; Zheng, Peiyi; Hu, Xiaowen; Jin, Tengchuan; Tan, Xu title: Profiling CD8+ T Cell Epitopes of COVID-19 Convalescents Reveals Reduced Cellular Immune Responses to SARS-CoV-2 Variants date: 2021-08-27 journal: Cell Rep DOI: 10.1016/j.celrep.2021.109708 sha: ad75c247b7534a029a7d578a693cad8db12c2ba5 doc_id: 878449 cord_uid: ai62bjvl Cellular immunity is important in determining disease severity of COVID-19 patients. However, current understanding of SARS-CoV-2 epitopes mediating cellular immunity is limited. Here we apply T-Scan, a recently developed method to identify CD8+ T cell epitopes from COVID-19 patients of four major HLA-A alleles. Several identified epitopes are conserved across human coronaviruses, which might mediate preexisting cellular immunity to SARS-CoV-2. In addition, we identify and validate four epitopes that were mutated in the newly circulating variants including the Delta variant. The mutations significantly reduce T cell responses to the epitope peptides in convalescent and vaccinated samples. We further determine the crystal structure of HLA-A∗02:01/HLA-A∗24:02 in complex with the epitope KIA_S/NYN_S respectively, which reveal the importance of K417 and L452 of the spike protein for binding to HLA. Our data suggest that evading cellular immunity might contribute to the increased transmissibility and disease severity associated with the new SARS-CoV-2 variants. The COVID-19 epidemic has caused infection of over 200 million people and deaths of over 4 million people worldwide as of August 2021 3 previously isolated neutralizing antibodies or convalescent sera from infection by the canonical SARS-CoV-2 variant (Cele et al., 2021; Chen et al., 2021; Collier et al., 2021; Halfmann et al., 2020; Hoffmann et al., 2021; Plante et al., 2021; Volz et al., 2021; Wang et al., 2021b) . These studies sounded alert to the efficacy of currently used vaccines and antibodies for the variants. However, these findings do not directly explain why these variants rapidly become dominating variants in certain countries and spread globally as most infected people are first-time infected and unvaccinated. There are also mixed findings regarding the infectivity of these variants, which might not be the main reason underlying their transmissibility (Hou et al., 2020; Neches et al., 2021; Ozono et al., 2021; Plante et al., 2021; Volz et al., 2021; Yurkovetskiy et al., 2020) . On the other hand of the adaptive immunity, cellular immunity has been shown to strongly correlate with disease outcome (Le Sattler et al., 2020; Sekine et al., 2020; Tan et al., 2021; Weiskopf et al., 2020) , which indicates the importance of understanding the difference in cellular immunity for the various variants. Previous studies have used limited number of synthetic peptides to identify epitopes that activates CD8 + T cells from COVID-19 patients or convalescents Kared et al., 2021; Le Bert et al., 2020; Peng et al., 2020; Schulien et al., 2021; Shomuradova et al., 2020; Weiskopf et al., 2020) . These studies have revealed a number of CD8 + T cell epitopes that are conserved between SARS-CoV-2 and other human coronaviruses that cause common cold, which provided evidence for pre-existing immunity in people previously infected by common-cold causing coronaviruses. One study used a systematic method named T-Scan to profile epitopes but they identified very few epitopes conserved across human coronaviruses (Ferretti et al., 2020) . Also surprisingly, few epitopes in the spike protein of SARS-CoV-2 was identified in this study compared with other studies (Ferretti et al., 2020; Le Bert et al., 2020; Shomuradova et al., 2020) . T-Scan utilizes a reporter cellbased epitope expressing library to incubate with human CD8 + T cells to identify epitopes that can activate CD8 + T cells in an unbiased fashion (Kula et al., 2019) . The reporter cells (EDCs, epitope discovery cells) over-express a HLA subtype and a peptide from the proteome of the interested pathogens. In addition, the EDCs also overexpress granzyme-B (GzB) expressing cassette and a modified infrared fluorescence protein (IFP) containing a GzB cleavage sequence with fluorescence appearance only J o u r n a l P r e -p r o o f 4 after being cleaved by GzB. When the EDCs presenting the cognate epitopes activate CD8 + T cells, which secrete GzB into the cognate EDCs to induce apoptosis, the modified IFP in the EDCs will be cleaved to activate the fluorescence signal. Flow cytometry-based sorting of the IFP positive EDCs and following next generation sequencing can identify the epitopes enriched in the sorted EDCs. Since the T-Scan method relies on the processing of the peptide library expressed in the EDCs, we applied the T-Scan method but with higher coverage of the proteome of SARS-CoV-2. We identified 52 high confidence epitope peptides from three prevalent HLA subtypes in Han Chinese recovered COVID-19 patients. We validated several novel epitopes that are conserved across human coronaviruses, further supporting pre-existing cellular immunity. Importantly, we validated three epitope peptides that are mutated in the We designed the EDC library to cover the whole SARS-CoV-2 proteome with overlapping 57-amino acid peptides in a step of one amino acid per peptide, totaling 9179 peptides ( Figure 1A) . We generated four EDC libraries which express one of four Further analysis takes advantages of the redundancy of epitope embedded in the peptide library as the HLA-I epitope usually contains 9-10 amino acids. For example, most 9mer epitopes are represented by 47 peptides in our library. To enrich highconfidence reoccurring epitopes, we require at least 8 peptides containing the same epitope to be enriched (Log2 > 4) to count as a hit epitope. We identified 70 high confidence epitopes based on this threshold and the NetMHC 4.0 server prediction scores (Strong binding scores based on the server), of which 20 have been identified in previous studies (Supplementary Table 2 ). As shown in Figure 1B - Figure 1E , our T-Scan screening strongly enriched peptides in ORF1a, ORF1b and S. Among these 70 epitopes, we identified several that are conserved between the human coronaviruses ( Figure 2A) . We validated seven epitopes using synthetic peptides and show that these peptides can activate CD8 + T cells from convalescent and several healthy donors based on an IFN- intracellular cytokine staining (ICS) assay ( Figure 2B and Supplementary Table 3 ) (Schulien et al., 2021) . We also generated the MHC tetramer complex for three of the HLA-A*02:01 restricted epitopes and showed that they could not only stain a subpopulation of the CD8 + T cells from a patient but one of two healthy donors tested ( Figure 2C ). Healthy donor H-01's CD8 + T cells showed staining to all three MHC tetramers while those of healthy donor H-02's did not show staining. The results of these peptides, together with previously reported results (Braun et al., 2020; Grifoni et al., 2020; Habel et al., 2020; Le Bert et al., 2020; Mateus et al., 2020; Schulien et al., 2021; Tarke et al., 2021; Weiskopf et al., 2020) , support that possibility of pre-existing cellular immunity in people not previously infected by SARS-CoV-2, which might contribute to the different disease severity between people. Given the growing prevalence and concerns of the SARS-CoV-2 variants, we the formation of the tetramer complex, also consistent with the predicted scores ( Figure 5C and 5G). Notably, mutations in both KIA_S and GVY_S are in the predicted anchoring sites of the epitopes, which are critical for epitope binding by the HLA protein (Oldstone, 1997) . L452R mutation did not prevent the formation of a complex with HLA-A*24:02 ( Figure 5H ), but the binding is likely formed through a different J o u r n a l P r e -p r o o f 8 conformation of epitope peptide with either reduced binding affinity or suboptimal recognition by TCR. Above all, we identified CD8 + T cells epitopes that were mutated in three SARS-CoV-2 variants, suggesting the evasion of cellular immunity by these variants. How the emerging variants virus rapidly become dominant is a burning question to understand the dynamics of the epidemic and is critical for vaccine and therapy development (Challen et al., 2021; Davies et al., 2021b; Duffy et al., 2008; Sette and Crotty, 2021) . Mounting evidence suggests these variants are resistant to currently available neutralizing antibodies generated against the original variant (Collier et al., 2021; Garcia-Beltran et al., 2021; Halfmann et al., 2020; Shen et al., 2021; Supasa et al., 2021; Wang et al., 2021a) . However, these data cannot explain the highly increased transmissibility of the variants in mostly previously-uninfected and unimmunized people. Furthermore, humoral immunity is not the only mechanism of host antiviral responses. Cellular immunity provides important host protection for reinfection (Kared et al., 2021; Nelde et al., 2021; Rha et al., 2021; Schulien et al., 2021) . To date, mixed results have been reported regarding the infectivity of these variants (Davies et al., 2021a; Hou et al., 2020; Ozono et al., 2021; Volz et al., 2021; Yurkovetskiy et al., 2020; Zhou et al., 2021) . A recent study has revealed that cellular immunity can be detected as early as 2-3 days from symptom onset and the strength of this early cellular immunity is strongly associated with mild disease and accelerated viral clearance(Le . Another study has reported mutations in the T cell epitopes of SARS-CoV-2 can help evade CD8 T cell response (Agerer et al., 2021) . Since the binding of CD8 + T cell epitopes to HLA molecule requires highly specific amino acid sequence of the epitope, evading cellular immunity provides an efficient way for the virus to gain advantages in replication and transmission. Here we provide evidence that evading cellular immunity might be a common characteristic of these dominating variants. We (Shomuradova et al., 2020) reported the CD8 + T cell reactivity to the KIA_S epitope in convalescent COVID-19 patients by MHC tetramer staining. This study examined the epitope specificity of the T cell immune response based on the NetMHC 4.0 prediction results (Andreatta and Nielsen, 2016) , and mainly reported two epitopes YLQ_S and RLQ_S, that elicited CD8 + T cells response in most of HLA-A*02:01 convalescents they tested. KIA_S was in the list of verified epitopes, which elicited CD8 + T cell response in 6/17 convalescents. Besides KIA_S, YLQ_S is also a hit in our T-Scan screening (Supplementary Table 2) , which attests to the robustness of our screening. Analysis using recombinant HLA protein and structure analysis using X-ray crystallography and computational modeling all suggested a weakened interaction of the mutant peptides to HLA than the original epitopes KIA_S, NYN_S and GVY_S. K417N mutation of KIA_S is a particularly wide-spread mutation, which cannot be explained by increasing infectivity or evading antibody neutralization (Greaney et al., 2021; Plante et al., 2021; Wang et al., 2021b) . Our data support that this mutation might provide the advantage of evasion of cellular immunity. L452R mutation has recently been reported to contribute to evasion from HLA-A24 mediated cellular immunity (Motozono et al., 2021) consistent with our findings. This mutation can also lead to increased viral infectivity, providing multiple benefits to the variants. Importantly, several VOCs harbor more than one mutation in the identified epitopes, providing a combinatorial effect to promote immune evasion covering multiple major HLA subtypes. In addition, our profiling has identified several epitopes that are highly conserved among human coronaviruses, particularly in the ORF1a and ORF1b. These epitopes can support pre-existing immunity in people, partially explaining the differential disease severity among the population. Importantly, vaccines incorporating these epitope sequences might therefore elicit broad antiviral cellular responses. In the study we demonstrated reduced CD8+ T cell responses to synthetic peptides containing the canonical or variant sequences using intracellular cytokine staining assay, which is a well-established surrogate assay commonly used by most studies on this subject (Motozono et al., 2021 Authors declare that they have no conflicts of interest. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Xu Tan (xutan@tsinghua.edu.cn). All unique/stable reagents generated in this study are indicated in the Key Resources Table and will be made available on request but may require a payment and/or a completed Materials Transfer Agreement if there is potential for commercial application.  We have deposited the diffraction data as well as PDB of the crystallography data to the RCSB PDB database with accession code 7KEU and 7F4W.  This paper does not report original code.  Any additional information required to reanalyze the data reported in this work paper is available from the Lead Contact upon request. All the E.coli strains used in this paper are cultured in 37℃ with the shaking speed of 220rpm. The resistant gene of each plasmid is labeled in the end of the corresponding plasmid name which can be found in the Key Resources Table. METHOD DETAILS The EDTA anticoagulant tubes were used to collect blood from recovered patients and To generate a complete set of potential SARS-CoV-2 antigens, we tiled across each ORF in 56 amino acids fragments with 55 amino acids overlap between adjacent tiles for a total of 9179 protein fragments. Fragment tiles were reverse translated using nonrare human codons. Each fragment was encoded by one nucleic acid sequence. The oligo library was synthesized with the following adaptors according to the method of For each HLA genotype, 20 million HEK293T cells (2100x library representation) expressing the SARS-CoV-2 library were co-cultured with 4 million HLA genotypematched memory CD8 + T cells of convalescent COVID-19 patients or healthy people for 12h, after which IFP GZB -positive target cells were sorted by flow cytometry (BD, Influx). The genomic DNA of collected target cells were extracted by GeneJET Genomic DNA Purification Kit (Thermo Fisher Scientific, and Cat # K0722) for the preparation of deepsequencing samples following the manuals (Novogene company). The sequencing data were analyzed by Bowtie (Mun et al., 2021) and Cutadapt (Kechin et al., 2017) . PBMCs were thawed and pulsed with peptides (1g/ml) and cultured in RPMI-1640 (Cat # R0883) with 10% FBS, 10 mM HEPES (Sigma), 2 mM GlutaMAX (Gibco), 50 IU/ml Pen-Strep (Sigma) and 50 IU IL-2 (Sigma, Cat # 11147528001) at a cell density of 1 million cells per ml. PBMCs were cultured for 10-12 days adding 100 IU IL-2 (Sigma, Cat # 11147528001) on day 5. The data were analyzed using linear-regression analysis in Figure 3F (n = 7); Wilcoxon SARS-CoV-2 mutations in MHC-Irestricted epitopes evade CD8(+) T cell responses reveals constraints on HIV-1 evolution Gapped sequence alignment using artificial neural networks: application to the MHC class I system SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccineelicited antibodies WHO validates Sinovac COVID-19 vaccine for emergency use and issue interim policy recommendations Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England Increased mortality in community-tested cases of SARS-CoV Rates of evolutionary change in viruses: patterns and determinants Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19 Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals Suboptimal SARS-CoV-2-specific CD8(+) T cell response associated with the prominent HLA-A*02:01 phenotype Transmission of SARS-CoV-2 in Domestic Cats SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals Adaptation of HIV-1 to human leukocyte antigen class I cutPrimers: A New Tool for Accurate Cutting of Primers from Reads of Targeted Next Generation Sequencing Crystal contacts as nature's docking solutions Inference of macromolecular assemblies from crystalline state T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls GalaxyPepDock: a protein-peptide docking tool based on interaction similarity and energy optimization Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity LevioSAM: Fast lift-over of variant-aware reference alignments Atypical Divergence of SARS-CoV-2 Orf8 from Orf7a within the Coronavirus Lineage Suggests Potential Stealthy Viral Strategies in Immune Evasion SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition How viruses escape from cytotoxic T lymphocytes: Molecular parameters and players SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 The variant gambit: COVID-19's next move PD-1-Expressing SARS-CoV-2-Specific CD8(+) T Cells Are Not Exhausted, but Functional in Patients with COVID-19 SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 Adaptive immunity to SARS-CoV-2 and COVID-19 SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity Antibody resistance of SARS-CoV-2 variants B Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant SARS-CoV-2 spike D614G change enhances replication and transmission